Evaluation of the risk of lung cancer associated with NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism in male current cigarette smokers from the Eastern India

Document Type : Short communication

Author

Department of Biotechnology and Dr B C Guha Centre for Genetic Engineering and Biotechnology,University College of Science and Technology, University of Calcutta, Kolkata -700019, India

Abstract

NAD(P)H: quinone oxidoreductase 1 (NQO1) is an endogenous cellular defence mechanism against several carcinogenic quinones derived from cigarette smoke. NQO1 C609T polymorphism is a strong determinant of NQO1 structure and function. The people with mutant allele for this polymorphism has significantly reduced NQO1 activity. In this study, we tried to evaluate the risk of lung cancer associated with this polymorphism in male current smokers of the Eastern India. Using PCR-RFLP method, we compared the NQO1 C609T genotype distribution in male current smokers with (n=150) and without (n=200) lung cancer. We observed significant variation of genotypic distribution between these two groups. The allele frequency of the variant C609T allele were 40.3% and 32.7% in smokers with and without lung cancer, respectively. From the genotypic comparison between the two smoker groups, it was found that a higher risk (OR=1.64, 95% CI: 1.05-2.55, p <0.05) of lung cancer was associated with NQO1 C609T polymorphism.

Keywords

References

1. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000; 129:77-97.
2. Das A, Dey N, Ghosh A, Das T, Chatterjee IB. NAD(P)H: Quinone oxidoreductase 1 deficiency conjoint with marginal vitamin C deficiency causes cigarette smoke-induced myelodysplastic syndromes. PLoS One.2011;6.
3. Joseph P, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci 1994;91:8413-8417.
4. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer THW, Danenberg PV, Ross D, Gibson NW. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res1992;52:797-802.
5. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD (P)H:quinone oxidoreductase 1. Mol Pharmacol 2001;59:263-268.
6. WHO. Cancer. Factsheet 297 (updated Feb 2018). Available from the following website:- http://www.who.int/mediacentre/factsheets/fs297/en/
7. CDC. Risk factor for lung cancer. Available from the following website.  https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm
8. United States Department of Health and Human Services. The Health Benefits of Smoking Cessation, 1990. DHHS Publication no. 90-8416.
9. Harris CC. Inter-individual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis (London) 1989;10:1563-1566.
10. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, Hatooka Sh, Mitsudomi T, Suyama M, Kagami Y, Ogura M, Ando M, Sugimura Y, Tajima K. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers in Japanese. Int J Clin Oncol 2002;7:103-108.
11. Saldivar SJ, Wang Y, Zhao H, Shao L, Lin J, Spitz MR, and Wu X. An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat Res 2005; 582:71-78.
12. Masroor M, Jain A, Javid J, Mir R, Prashant Y, Imtiyaz A, Mariyam Z, Mohan A, Ray PC,               Saxena A. Clinical significance of the NQO1 C609T polymorphism in non small cell lung adenocarcinoma patients.  Asian Pac J Cancer  2015;16;7653-7658.
13. Malik MA, Zargar SA, Mittal B. Role of NQO1 609C>T and NQO2 -3423G>A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis. Mol Biol Rep 2012; 39:9095-9104.
14. Umar M, Upadhyay R, Kumar S, Ghoshal UC, Mittal B. Null association of NQO1 609C>T and NQO2 3423G>A polymorphisms with susceptibility and prognosis of Esophageal cancer in north Indian population and meta-analysis. Cancer Epidemiol 2012;36:e373-379.
15. Global Adult Tobacco Survey (GATS). Fact Sheet.India:2009-2010. Available from the following website:http://www.who.int/tobacco/surveillance/en_tfi_india_gats_fact_sheet.pdf
16. Chen H, Lum A, Seifried A,Wilkens LR, Marchand LL. Association of the NAD(P)H:quinone oxidoreductase 609CàT polymorphism with a decreased lung cancer risk. Cancer Res 1999;59,3045-3048.
17. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD (P) H: quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995;5:199-206.
18. De Flora S, Bennicelli C, D’Agostini F, Izzotti A, Camoirano A. Cytosolic activation of aromatic and heterocyclic amines. Inhibition by dicoumarol and enhancement in viral hepatitis B. Environ Health Perspect 1994;102:69-74.
19. Chen S, Knox R, Lewis AD, Friedlis F, Workman P, Deng PS, Fung M, Ebenstein D, Wu K, Tsai TM. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes. Mol Pharmacol 1995;47: 934-939.
20. Cenas N, Nemeikaite A, Dickancaite E, Anusevicius Z, Nivinskas H, Bironaite D. The toxicity of aromatic nitrocompounds to bovine leukemia virus-transformed fibroblasts: the role of single electron reduction. Biochem Biophy Acta1995; 1268:159-164.

Files

Share

How to cite

Statistics